Dr.ObesityLA said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
Fair, and it stops being fair at the extremes. The middle of the range is well understood; the ends are where the honest answer is that nobody knows.
Dr.DermMIA said:The pharmacokinetics explain nearly every practical question asked here.
Saving this. It is the first explanation that did not require me to already understand it. Sending this to two other people who asked me the same thing last week.
Dr.ObesityLA said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
Pushing back on Dr.ObesityLA here. I think the framing smuggles in the conclusion. Ask it the other way round and the obvious answer reverses, which usually means the question is doing the work.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne concrete data point for the thread. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.
Moderator note: the sourcing question belongs in the vendor section and has been split out. Tagging this one for the weekly digest.